Article
TNFAIP3 mutation is an independent poor overall survival factor for patients with T-cell acute lymphoblastic leukemia.
Cancer medicine - 1 Feb 2023
Chen Cunte, Zhou Lingling, Zhu Lihua, Luo Gengxin, Wang Liang, Zeng Chengwu, Zhou Hongsheng, Li Yangqiu
Abstract excerpt
BACKGROUND: It is imperative to explore potential biomarkers for predicting clinical outcome and developing targeted therapies for T-cell acute lymphoblastic leukemia (T-ALL). This study aimed to investigate the mutation patterns of tumor necrosis factor-alpha-inducing protein 3 (TNFAIP3, also known as A20) and its role in the prognosis of T-ALL patients. METHODS: Polymerase chain reaction (PCR) and Sanger...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
